FDC Ltd share Price

FDC Ltd. is an Indian company engaged in the business of pharmaceuticals. It initiated the concept of Oral Rehydration Salts (ORS) and is now a pioneer in the segment with its brand Electral. The company was founded in 1936, with its headquarters in Aurangabad, Maharashtra. During the June 2022 quarter, its total income was Rs 513.79 crore, up 46.49% from the previous March 2022 quarter. On 27 October 2022, FDC Ltd.’s market capitalisation stood at Rs 5,006 crore.

The company is listed on the Bombay Stock Exchange with the code FDC and on the National Stock Exchange with the code 531599.

FDC Ltd. manufactures and distributes a range of generics, formulations, and active pharmaceutical ingredients (API) at its manufacturing plants. It also produces functional foods and beverages. Pyrimon, Cotaryl, Zifi, Enerzal, Electral, Vitcofol, Zathrin, Zoxan, Zocon, Zefu, Mycoderm, and Zipod are some of the brands owned by the company.

On 30 June 2022, FDC Ltd.’s shareholding pattern showed public holdings of 20.1%, domestic institutional investor holdings of 6.08%, foreign institutional investor holdings of 4.34%, and promoter holdings of 69.5%. Ms Meera Ramdas Chandavarkar is the leading promoter, with a 19.4% share.

The company’s top management comprises Mr Ramdas A Chandavarkar, Mr Nandan M Chandavarkar, Mr Ashok A Chandavarkar, Dr Mahesh Bijlani, Mr Sanjay Jain, Mr Mohan A Chandavarkar, CA Uday Kumar Gurkar, Mr Ameya A Chandavarkar, Mr Melarkode Ganesan Parameswaran, Ms Nomita R Chandavarkar, CA Swati S Mayekar, Ms Varsharani Kate, and Ms Usha Athreya Chandrasekhar. The company’s auditors are B S R & Co. LLP. As of 30 June 2022, the company’s total number of outstanding shares was 16.59 crores.

On 27 October 2022, the company’s share price was trending at Rs 301.95 on BSE and Rs 301.75 on NSE. The company’s highest share price in 52 weeks was Rs 345, and the lowest price was Rs 225. By investing in FDC Ltd.’s shares, investors earned a six-month return of 9.26% and a one-year return of -7.97%.

As of September 2022, ICICI Prudential Pharma Healthcare and Diagnostics (P H D) Fund had a 3.21% stake in FDC Ltd. The company’s other mutual fund holdings include Tata India Pharma & Healthcare Fund, ITI Pharma and Healthcare Fund, and ICICI Prudential ESG Fund, with 2.39%, 1.93%, and 1.12% stakes, respectively.

Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.